|
Document Title |
Date of Publication |
Previous Versions and Notes |
|---|---|---|
|
November 2025 |
July 2025 December 2024 |
|
|
Daptomycin to treat infections with enterococci or coagulase-negative staphylococci |
December 2025 |
|
|
Guidance on the use of cephalosporins in Staphylococcus aureus |
February 2025 |
2025, 2023 |
|
Guidance on antimicrobial agents for Stenotrophomonas maltophilia |
15 November 2024 |
February 2012
See also the narrative review in CMI (2025) |
|
September 2024 |
29 February 2024 30 June 2023 December 2021 - 30 June 2023 July 2016 - December 2021 |
|
|
28 May 2024 |
December 2023 |
|
|
8 February 2024 |
Originally published 2018; updated 2019, 2020, 2022, and 8 February 2024
Graphs to illustrate ATUs (Updated 5 February 2024) |
|
|
1 January 2024 |
See also the Warning on cefiderocol susceptibility testing |
|
|
Guidance on the Implementation of Revised Aminopenicillin Breakpoints for Enterobacterales |
15 September 2023 |
|
|
Phenotypic screening tests to detect and exclude resistance of clinical relevance |
22 August 2022 |
13 June 2022 2 February 2022 1 December 2021 |
|
21 July 2022 |
23 December 2018 |
|
|
12 April 2022 |
21 November 2019 22 December 2016 |
|
|
Implementation and use of the 2022 revised colistin breakpoints |
January 2022 |
November 2021 |
|
January 2022 |
13 July 2018 |
|
|
14 December 2021 |
2 October 2017 |
|
|
2 December 2021 |
||
|
14 July 2020 |
16 February 2012 |
|
|
30 May 2021 |
11 December 2017 |
|
|
Implementation and use of the 2020 revised aminoglycoside breakpoints |
21 January 2020 |
April 2020 |
|
Guidance for industry on the working order between pharmaceutical industry, EMA and EUCAST |
5 May 2019 |
|
|
Cefotaxime and ceftazidime disks with and without clavulanic acid for ESBL confirmation |
12 February 2019 |
|
|
The 2019 modifications of susceptibility categories S, I and R categories |
22 October 2018 |
This presentation also informs laboratories on how to implement the Area of Technical Uncertainty. |
|
22 March 2016 |
||
|
20 July 2013 |
||
|
16 February 2012 |
See also EUCAST Rapid AST directly from positive blood culture bottles |
|
Document Title |
Date of Publication |
Previous Versions and Notes |
|---|---|---|
|
28 May 2024 |
December 2023 |
|
|
1 January 2024 |
See also the Warning on cefiderocol susceptibility testing |
|
|
12 April 2022 |
21 November 2019 22 December 2016 |
|
|
21 July 2022 |
23 December 2018 |
|
|
Implementation and use of the 2022 revised colistin breakpoints |
January 2022 |
November 2021 |
|
Implementation and use of the 2020 revised aminoglycoside breakpoints |
21 January 2020 |
April 2020 |
|
Cefotaxime and ceftazidime disks with and without clavulanic acid for ESBL confirmation |
12 February 2019 |
|
|
22 March 2016 |
|
Document Title |
Date of Publication |
Previous Versions and Notes |
|---|---|---|
|
July 2025 |
December 2024 |
|
|
Daptomycin to treat infections with enterococci or coagulase-negative staphylococci |
December 2025 |
|
Document Title |
Date of Publication |
Previous Versions and Notes |
|---|---|---|
|
September 2024 |
29 February 2024 30 June 2023 December 2021 - 30 June 2023 July 2016 - December 2021 |
|
|
8 February 2024 |
Originally published 2018; updated 2019, 2020, 2022, and 8 February 2024
Graphs to illustrate ATUs (Updated 5 February 2024) |
|
|
Phenotypic screening tests to detect and exclude resistance of clinical relevance |
22 August 2022 |
13 June 2022 2 February 2022 1 December 2021 |
|
January 2022 |
13 July 2018 |
|
|
14 December 2021 |
2 October 2017 |
|
|
2 December 2021 |
||
|
The 2019 modifications of susceptibility categories S, I and R categories |
22 October 2018 |
This presentation also informs laboratories on how to implement the Area of Technical Uncertainty. |
|
16 February 2012 |
See also EUCAST Rapid AST directly from positive blood culture bottles |
|
Document Title |
Date of Publication |
Previous Versions and Notes |
|---|---|---|
|
Guidance on the use of cephalosporins in Staphylococcus aureus |
February 2025 |
2025, 2023 |
|
Guidance on antimicrobial agents for Stenotrophomonas maltophilia |
15 November 2024 |
February 2012
See also the narrative review in CMI (2025) |
|
Guidance on the Implementation of Revised Aminopenicillin Breakpoints for Enterobacterales |
15 September 2023 |
|
|
30 May 2021 |
11 December 2017 |
|
|
14 July 2020 |
16 February 2012 |
|
|
20 July 2013 |
|
Document Title |
Date of Publication |
Previous Versions and Notes |
|---|---|---|
|
Guidance for industry on the working order between pharmaceutical industry, EMA and EUCAST |
5 May 2019 |
For previous versions of documents, see the document archive.
Looking for more information? Get in touch with an EUCAST representative today!